This inventor holds 1 USPTO granted patent. Top assignee: Taiho Pharmaceutical Company Limited. Active years: 2007.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2007
Title: Mitsuo Ohta: Innovator in Lung Cancer Treatment
Introduction
Mitsuo Ohta is a prominent inventor based in Fukuoka, Japan. He has made significant contributions to the field of oncology, particularly in the treatment of lung cancer. His innovative approach has the potential to improve the quality of life for patients undergoing postoperative care.
Latest Patents
Mitsuo Ohta holds a patent for "Postoperative adjuvant chemotherapy with UFT." This invention provides an improved method for treating lung cancer, specifically non-small cell lung cancer, by orally administering UFT to postoperative lung cancer patients. This advancement represents a crucial step in enhancing treatment efficacy and patient outcomes.
Career Highlights
Ohta is associated with Taiho Pharmaceutical Company Limited, where he has been instrumental in developing new therapeutic strategies. His work focuses on improving cancer treatment protocols, showcasing his dedication to advancing medical science.
Collaborations
Mitsuo Ohta has collaborated with notable colleagues, including Hiromi Wada and Harubumi Kato. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of cancer research.
Conclusion
Mitsuo Ohta's contributions to lung cancer treatment through his patent and work at Taiho Pharmaceutical Company Limited highlight his commitment to improving patient care. His innovative methods pave the way for future advancements in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile